Company registration number: 04452715



Alliance Boots Holdings Limited Strategic report, Directors' report and financial statements for the year ended 31 August 2017

Contents

Strategic report
Directors' report
Directors' responsibilities statement
Independent auditors' report
Income statement
Statement of comprehensive income
Balance sheet
Statement of changes in equity
Notes to the financial statements

Strategic report

for the year ended 31 August 2017

Principal activities

Alliance Boots Holdings Limited (the "Company") is an investment holding company within the Walgreens Boots Alliance, Inc. consolidated group ("Group").

Business review

	2017 £million	2016 £million
Operating loss	(83)	(2)
Profit for the year	1,898	1,115
Fair value movements on investments classified as held for sale	(33)	-
Total Equity	7,608	6,900

On 25 July 2017, the Group announced its intent to enter into a 10-year global agreement for the manufacture and supply of own beauty brands and private label products with Fareva S.A. Under the terms of the offer, Fareva S.A. will take ownership of the Group's contract manufacturing business, which includes BCM Limited, BCM Specials Limited and BCM Employment & Management Services Limited, entities fully owned by the Company. The sale did not complete until 31 October 2017. As such the investments in BCM Limited, BCM Specials Limited and BCM Employment & Management Services Limited were classified as held for sale as at the balance sheet date.

Principal risks and uncertainties

The Company's Directors monitor the overall risk profile of the Company. In addition, the Directors are responsible for determining clear policies as to what the Company considers to be acceptable levels of risk. These policies seek to enable people throughout the Company to use their expertise to identify risks that could undermine performance and to devise ways of bringing them to within acceptable levels. Where the Directors identify risks that are not acceptable, they develop action plans to mitigate them with clear allocation of responsibilities and timescales for completion and ensure that progress towards implementing these plans is monitored and reported upon.

By order of the Board:

Frank Standish

Director

30 November 2017

Directors' report

for the year ended 31 August 2017

The Directors present their report and the audited financial statements for the year ended 31 August 2017.

Going concern

The Company's business activities, together with the factors likely to affect its future development and position, are set out in its strategic report.

The financial statements have been prepared on a going concern basis, notwithstanding net current liabilities of £2,023 million (2016: £50million) which as disclosed in notes 15, 16 and 17 primarily relates to loans with fellow group undertakings.

The Company is expected to continue to generate positive cash flows on its own account for the foreseeable future. The Company acts as one of primary treasury and holding entities in the Group. As such it manages material cash flows generated by WBA subsidiary undertakings and provides lending arrangements on an arm's length basis to its subsidiaries and to its affiliates in line with financial plans approved by WBA. The Directors note that interest income from subsidiaries was £286 million (2016: £241 million) and dividend income was £1,718 million (2016: £909 million). In addition the Company has no external debts or covenants and has net assets of £7,608 million (2016: £6,900 million).

On the basis of their assessment of the Company's financial position, the Company's Directors have a reasonable expectation that the Company will be able to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the annual financial statements.

Financial instruments

The Company is exposed to currency, credit and interest rate risk. The Group's treasury function manages these risks at a Group level in accordance with Group Treasury Policy including the use of financial instruments for the purpose of managing these risks. Group risks are discussed in the Group's Annual Report, which does not form part of this report.

Dividends

A dividend of £1,157 million was declared and paid in the year (2016: £1,066 million). Further details can be found in note 9 of the financial statements.

Future developments

The Company intends to continue operating as a holding company within the Group.

Post balance sheet events

On 30 October 2017 the Company subscribed to one share in BCM Limited for consideration of £29 million.

On 31 October 2017, the Group entered into a 10-year global agreement for the manufacture and supply of own beauty brands and private label products with Fareva S.A. In return, Fareva S.A. took full ownership of the Group's contract manufacturing business, which included BCM Limited, BCM Specials Limited and BCM Employment & Management Services Limited, entities fully owned by the Company.

On 21 November 2017, the Company disposed of its investment in Boots Retail (Thailand) Limited for \$106 million (£80 million).

Directors

The following served as Directors during the year and to the date of this report:

Aidan Clare

Martin Delve

(resigned 6 February 2017)

Frank Standish

Mark Muller

(appointed 6 February 2017)

The Directors benefited from qualifying third party indemnity provisions in place during the financial year and at the date of this report.

Audito

Pursuant to s487 Companies Act 2006, Deloitte LLP were deemed to be reappointed and will therefore continue in office.

Disclosure of information to auditors

The Directors who held office at the date of approval of this Directors' report confirm that, so far as they are each aware, there is no relevant audit information of which the Company's auditor is unaware; and each Director has taken all the steps that they ought to have taken as a Director to make themselves aware of any relevant audit information and to establish that the Company's auditor is aware of that information.

This confirmation is given and should be interpreted in accordance with the provisions of s418 of the Companies Act of 2006.

By order of the Board:

Frank Standish

Director

30 November 2017

Registered office:

Sedley Place

4th Floor 361 Oxford Street

London

W1C 2JI

Registered in England and Wales No. 04452715

Directors' responsibilities statement

for the year ended 31 August 2017

The Directors are responsible for preparing the Strategic report, Directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law), including FRS 101 'Reduced Disclosure Framework'.

Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

- · select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- · prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Independent auditors' report

to the members of Alliance Boots Holdings Limited

Report on the audit of the financial statements

Opinion

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 August 2017 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice including Financial Reporting Standard 101 "Reduced Disclosure Framework"; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements of Alliance Boots Holdings Limited (the 'company') which comprise:

- · the profit and loss account:
- the statement of comprehensive income
- the balance sheet;
- the statement of changes in equity; and
- the related notes 1 to 23.

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 101 "Reduced Disclosure Framework" (United Kingdom Generally Accepted Accounting Practice).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs(UK)) and applicable law. Our responsibilities under those standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report.

We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We are required by ISAs (UK) to report in respect of the following matters where:

- . the directors' use of the going concern basis of accounting in preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the
 company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the
 financial statements are authorised for issue.

We have nothing to report in respect of these matters.

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in respect of these matters.

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Independent auditors' report (continued)

to the members of Alliance Boots Holdings Limited

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Report on other legal and regulatory requirements

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- · the strategic report and the directors' report have been prepared in accordance with applicable legal requirements.

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified any material misstatements in the strategic report or the directors' report.

Matters on which we are required to report by exception

Under the Companies Act 2006 we are required to report in respect of the following matters if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us;
 or
- the financial statements are not in agreement with the accounting records and returns; or
- · certain disclosures of directors' remuneration specified by law are not made; or
- · we have not received all the information and explanations we require for our audit.

We have nothing to report in respect of these matters.

SBUTTION

S Butters FCA (Senior statutory auditor) for and on behalf of Deloitte LLP Statutory Auditor Reading, United Kingdom

30 November 2017

Income statement

for the year ended 31 August 2017

	Notes	2017 £million	2016 £million
Other operating expenses		(83)	(2)
Operating loss		(83)	(2)
Income from shares in Group undertakings		1,718	909
Investment revenue	'6 [.]	373	314
Finance costs	7	(96)	(104)
Profit before taxation		1,912	1,117
Tax	. 8	`(14)	(2)
Profit for the year		1,898	1,115

Operating loss is all derived from continuing operations.

Statement of comprehensive income

for the year ended 31 August 2017

	Notes	2017 £million	2016 £million
Profit for the year		1,898	1,115
Other comprehensive loss for the year			
Items that will not be reclassified subsequently to profit or loss:			
Fair value movements on investments classified as held for sale	13	(33)	<u> </u>
Total comprehensive gain for the year		1,865	1,115

The accompanying notes to the financial statements are an integral part of the Company's financial statements.

Balance sheet

As at 31 August 2017

	Notes	2017 £million	2016 £million
Assets			
Non-current assets			
Investments in subsidiaries	10	10,810	11,051
Interests in associates	11	11	29
Other investments	12	32	16
		10,853	11,096
Current assets			
Investments classified as held for sale	13	40	-
Trade and other receivables	14	2,307	1,609
Derivative financial instruments	15,21	8	33
Cash and bank balances	•	1,159	1,024
		3,514	2,666
Total assets		14,367	13,762
Liabilities		•	
Current liabilities			
Borrowings	. 16	(2,201)	(530)
Trade and other payables	17	(3,316)	(2,180)
Derivative financial instruments	15,21	(20)	(6)
		(5,537)	(2,716)
Net current liabilities		(2,023)	(50)
Total assets less current liabilities		8,830	11,046
Non-current liabilities			
Borrowings	16	(1,222)	(4,146)
Net assets		7,608	6,900
E-milhi.			
Equity Share conital	18	362	362
Share capital	. 19		2,071
Share premium account	20	29	2,071
Capital redemption reserve	. 20	7,217	4,438
Profit and loss account	. 20	7,608	6,900
Total equity	<u> </u>	7,000	0,900

The accompanying notes to the financial statements are an integral part of the Company's financial statements.

The financial statements of Alliance Boots Holdings Limited were approved by the Board of Directors and authorised for issue on 30 November 2017. They were signed on its behalf by:

Mark Muller Director

Statement of changes in equity for the year ended 31 August 2017

	,	Share capital £million	Share premium account £millión	Capital redemption reserve £million	Profit and loss account £million	Total £million
At 1 September 2015	•	362	2,071	29	4,389	6,851
Profit for the year	å	=	=	•	1,115	1,115
Issue of share capital		-	. -	-	(1,066)	(1,066)
At 31 August 2016	,	362	2,071	29	4,438	6,900
Share premium reduction	•	•	(2,071)	-,	2,071	-
Profit for the year		•	•	•	1,898	1,898
Dividends paid	·	4	•	-	(1,157)	(1,157)
Other comprehensive income		•	. •	, ,	(33)	(33)
At 31 August 2017		362	•	29	7,217	7,608

The accompanying notes to the financial statements are an integral part of the Company's financial statements.

Notes to the financial statements

for the year ended 31 August 2017

1. General information

The Company is a private Company limited by shares and is registered in England and Wales.

The address of the registered office is given on page 2.

The nature of the Company's operations and its principal activities are set out in the Strategic report on page 1.

2. Significant accounting policies

Basis of accounting

These financial statements are presented in pounds sterling because that is the currency of the primary economic environment in which the Company operates.

These financial statements are individual accounts. The Company is exempt from the preparation of consolidated financial statements, because it is included in the group financial statements of Walgreens Boots Alliance, Inc. The group accounts of Walgreens Boots Alliance, Inc. are available from the Walgreens Boots Alliance website at www.walgreensbootsalliance.com. The principal office of the parent company preparing consolidated financial statements is 108 Wilmot Road, Deerfield, Illinois, 60015, United States of America.

These financial statements were prepared in accordance with Financial Reporting Standard 101 Reduced Disclosure Framework ("FRS 101"). The financial statements have been prepared on the historical cost basis, except financial instruments that are measured at fair values at the end of each reporting period, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for the goods and services. Where relevant, equivalent disclosures have been given in the group accounts of Walgreens Boots Alliance, Inc.

The Company has taken advantage of the following disclosure exemptions under FRS 101:

- (a) the requirements of paragraph 33(c) of IFRS 5 Non-current Assets Held for Sale and Discontinued Operations;
- (b) the requirements of IFRS 7 Financial Instruments: Disclosures;
- (c) the requirements of paragraphs 91-99 of IFRS 13 Fair Value Measurement;
- (d) the requirements of paragraphs 10(d), 10(f), 16, 38A, 38B, 38C, 38D, 40A, 40B, 40C, 40D, 111 and 134-136 of IAS 1 Presentation of Financial Statements:
- (e) the requirements of IAS 7 Statement of Cash Flows;
- (f) the requirements of paragraph 17 of IAS 24 Related Party Disclosures; and
- (g) the requirements in IAS 24 Related Party Disclosures to disclose related party transactions entered into between two or more members of a group, provided that any subsidiary which is a party to the transaction is wholly owned by such a member.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics of the asset or liability in the participants would take those characteristics of the asset or liability at the measurement date. Fair value for measurement purposes in these financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of IFRS 2, leasing transactions that are within the scope of IAS 17, and measurements that have some similarities to fair value but are not fair value, such as net realisable value in IAS 2 or value in use in IAS 36.

The principal accounting policies adopted are set out below.

Going concern

The Company's business activities, together with the factors likely to affect its future development and position, are set out in its Strategic report.

The Company is expected to continue to generate positive cash flows on its own account for the foreseeable future. The Company acts as one of primary treasury and holding entities in the Group. As such it manages material cash flows generated by WBA subsidiary undertakings and provides lending arrangements on an arm's length basis to its subsidiaries and to its affiliates in line with financial plans approved by WBA. The Directors note that interest income from subsidiaries was £286 million (2016: £241 million) and dividend income was £1,718 million (2016: £909 million). In addition the Company has no external debts or covenants and has net assets of £7,608 million (2016: £6,900 million).

On the basis of their assessment of the Company's financial position, the Company's Directors have a reasonable expectation that the Company will be able to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the annual financial statements.

Changes in accounting policies and disclosures

In the current year, the Company has applied amendments to IFRSs that were issued by the International Accounting Standards Board (IASB) and endorsed for use in the European Union and are mandatorily effective for an accounting period that begins on or after 1 January 2016. Their adoption has not had any material impact on the disclosures or on the amounts reported in these financial statements.

Amendments to IAS 1 Disclosure Initiative: The Company has adopted the amendments to IAS 1 Disclosure Initiative for the first time in the current
year. The amendments clarify that an entity need not provide a specific disclosure required by an IFRS if the information resulting from that disclosure
is not material, and give guidance on the bases of aggregating and disaggregating information for disclosure purposes. However, the amendments
reiterate that an entity should consider providing additional disclosures when compliance with the specific requirements in IFRS is insufficient to
enable users of financial statements to understand the impact of particular transactions, events and conditions on the entity's financial position and
financial performance.

In addition, the amendments clarify that an entity's share of the other comprehensive income of associates and joint ventures accounted for using the equity method should be presented separately from those arising from the Company, and should be separated into the share of items that, in

Notes to the financial statements (continued)

for the year ended 31 August 2017

2. Significant accounting policies (continued)

accordance with other IFRSs: (i) will not be reclassified subsequently to profit or loss; and (ii) will be reclassified subsequently to profit or loss when specific conditions are met.

The amendments also address the structure of the financial statements by providing examples of systematic ordering or grouping of the notes.

- Amendments to IAS 16 and IAS 38 Clarification of Acceptable Methods of Depreciation and Amortisation: The Company has adopted the
 amendments to IAS 16 and IAS 38 Clarification of Acceptable Methods of Depreciation and Amortisation for the first time in the current year. The
 amendments to IAS 16 prohibit entities from using a revenue-based depreciation method for items of property, plant and equipment. The
 amendments to IAS 38 introduce a rebuttable presumption that revenue is not an appropriate basis for amortisation of an intangible asset. This
 presumption can only be rebutted in the following two limited circumstances:
 - (a) when the intangible asset is expressed as a measure of revenue; or
 - (b) when it can be demonstrated that revenue and consumption of the economic benefits of the intangible asset are highly correlated.
- Annual Improvements to IFRSs 2012-2014 Cycle: The Company has adopted the amendments to IFRSs included in the Annual Improvements to IFRSs 2012 - 2014 Cycle for the first time in the current year.

The amendments to IFRS 5 introduce specific guidance in IFRS 5 for when an entity reclassifies an asset (or disposal group) from held for sale to held for distribution to owners (or vice versa). The amendments clarify that such a change should be considered as a continuation of the original plan of disposal and hence requirements set out in IFRS 5 regarding the change of sale plan do not apply. The amendments also clarifies the guidance for when held-for-distribution accounting is discontinued.

The amendments to IFRS 7 provide additional guidance to clarify whether a servicing contract is continuing involvement in a transferred asset for the purpose of the disclosures required in relation to transferred assets.

The amendments to IAS 19 clarify that the rate used to discount post-employment benefit obligations should be determined by reference to market yields at the end of the reporting period on high quality corporate bonds. The assessment of the depth of a market for high quality corporate bonds should be at the currency level (i.e. the same currency as the benefits are to be paid). For currencies for which there is no deep market in such high quality corporate bonds, the market yields at the end of the reporting period on government bonds denominated in that currency should be used instead.

Investments in subsidiaries

Investments in subsidiaries are accounted for at cost less, where appropriate, provisions for impairment.

Investments in associates

An associate is an entity over which the Company has significant influence and that is neither a subsidiary nor an interest in a joint venture. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those policies.

Investments in associates are accounted for at cost less, where appropriate, provisions for impairment.

Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable net of sales-related taxes.

Dividend and interest revenue

Dividend income from investments is recognised when the shareholders' rights to receive payment have been established (provided that it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably).

Interest income is recognised when it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Foreign currencies

Currency transactions

Transactions denominated in currencies other than an entity's functional currency are translated into an entity's functional currency at the exchange rates prevailing at the date of the transactions. Monetary assets and liabilities denominated in currencies other than an entity's functional currency at the year-end are translated at the exchange rate ruling at that date. Non-monetary assets and liabilities that are measured at historical cost and are denominated in currencies other than an entity's functional currency are translated using the exchange rates at the date of the transaction. Non-monetary items that are measured at fair value and are denominated in currencies other than an entity's functional currency are translated using the exchange rates at the date when the fair value was determined. Exchange gains and losses are recognised in the income statement.

Taxation

The tax expense represents the sum of the current tax and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.

Current tax and deferred tax for the year

Current and deferred tax are recognised in profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax are also recognised in other comprehensive income or directly in equity respectively.

Cash and bank balances

Cash and bank balances comprises cash in hand and short term deposits with maturities of three months or less from the date of acquisition. Bank overdrafts are shown within borrowings in current liabilities on the Balance sheet.

Notes to the financial statements (continued)

for the year ended 31 August 2017

2. Significant accounting policies (continued)

Financial instruments

Financial assets and financial liabilities are recognised in the Company's balance sheet when the Company becomes a party to the contractual provisions of the instrument. Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognised immediately in profit or loss.

Financial assets

All financial assets are recognised and derecognised on a trade date where the purchase or sale of a financial asset is under a contract whose terms require delivery of the financial asset within the timeframe established by the market concerned, and are initially measured at fair value, plus transaction costs, except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value.

Financial assets are classified into the following specified categories: 'held-to-maturity' investments, 'available-for-sale' (AFS) financial assets and 'loans and receivables'. The classification depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

Effective interest method

The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocating interest income over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the debt instrument, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

Income is recognised on an effective interest basis for debt instruments.

Available for sale (AFS) financial assets

AFS financial assets are non-derivatives that are either designated as AFS or are not classified as (a) loans and receivables, (b) held-to-maturity investments or (c) financial assets at fair value through profit or loss.

AFS equity investments that do not have a quoted market price in an active market and whose fair value cannot be reliably measured and derivatives that are linked to and must be settled by delivery of such unquoted equity investments are measured at cost less any identified impairment losses at the end of each reporting period.

Loans and receivables

Trade receivables, loans, and other receivables that have fixed or determinable payments that are not quoted in an active market are classified as 'loans and receivables'. Loans and receivables are measured at amortised cost using the effective interest method, less any impairment. Interest income is recognised by applying the effective interest rate, except for short-term receivables when the recognition of interest would be immaterial.

Impairment of financial assets

Financial assets are assessed for indicators of impairment at each balance sheet date. Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows of the investment have been affected.

For listed and unlisted equity investments classified as AFS, a significant or prolonged decline in the fair value of the security below its cost is considered to be objective evidence of impairment.

For all other financial assets, including redeemable notes classified as AFS, objective evidence of impairment could include:

- · significant financial difficulty of the issuer or counterparty; or
- default or delinquency in interest or principal payments; or
- it becoming probable that the borrower will enter bankruptcy or financial re-organisation.

For certain categories of financial asset, such as trade receivables, assets that are assessed not to be impaired individually are, in addition, assessed for impairment on a collective basis. Objective evidence of impairment for a portfolio of receivables could include the Company's past experience of collecting payments, an increase in the number of delayed payments in the portfolio past the average credit period, as well as observable changes in national or local economic conditions that correlate with default on receivables.

For financial assets carried at amortised cost, the amount of the impairment is the differences between the asset's carrying amount and the present value of estimated future cash flows, discounted at the financial asset's original effective interest rate.

The carrying amount of the financial asset is reduced by the impairment loss directly for all financial assets with the exception of trade receivables, where the carrying amount is reduced through the use of an allowance account. When a trade receivable is considered uncollectible, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are credited against the allowance account. Changes in the carrying amount of the allowance account are recognised in profit or loss.

When an AFS financial asset is considered to be impaired, cumulative gains or losses previously recognised in other comprehensive income are reclassified to profit or loss in the period.

With the exception of AFS equity instruments, if, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed through profit or loss to the extent that the carrying amount of the investment at the date the impairment is reversed does not exceed what the amortised cost would have been had the impairment not been recognised.

In respect of AFS equity securities, impairment losses previously recognised in profit or loss are not reversed through profit or loss. Any increase in fair value subsequent to an impairment loss is recognised in other comprehensive income and accumulated under the heading of investments revaluation reserve. In respect of AFS debt securities, impairment losses are subsequently reversed through profit or loss if an increase in the fair value of the investment can be objectively related to an event occurring after the recognition of the impairment loss.

Notes to the financial statements (continued)

for the year ended 31 August 2017

2. Significant accounting policies (continued)

Derecognition of, financial assets

The Company derecognises a financial asset only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another entity. If the Company neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Company recognises its retained interest in the asset and an associated liability for amounts it may have to pay. If the Company retains substantially all the risks and rewards of ownership of a transferred financial asset, the Company continues to recognise the financial asset and also recognises a collateralised borrowing for the proceeds received.

On derecognition of a financial asset in its entirety, the difference between the asset's carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognised in other comprehensive income and accumulated in equity is recognised in profit or loss.

On derecognition of a financial asset other than in its entirety (e.g. when the Company retains an option to repurchase part of a transferred asset), the Company allocates the previous carrying amount of the financial asset between the part it continues to recognise under continuing involvement, and the part it no longer recognises on the basis of the relative fair values of those parts on the date of the transfer. The difference between the carrying amount allocated to the part that is no longer recognised and the sum of the consideration received for the part no longer recognised and any cumulative gain or loss allocated to it that had been recognised in other comprehensive income is recognised in profit or loss. A cumulative gain or loss that had been recognised in other comprehensive income is allocated between the part that continues to be recognised and the part that is no longer recognised on the basis of the relative fair values of those parts.

Financial liabilities and equity

Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangement.

Financial liabilities

Financial liabilities, including borrowings, are initially measured at fair value, net of transaction costs.

Financial liabilities are subsequently measured at amortised cost using the effective interest method, with interest expense recognised on an effective yield basis.

The effective interest method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments through the expected life of the financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

Derecognition of financial liabilities

The Company derecognises financial liabilities when, and only when, the Company's obligations are discharged, cancelled or they expire.

Derivative financial instruments

The Company enters into a variety of derivative financial instruments to manage its exposure to interest rate and foreign exchange rate risk, including foreign exchange forward contracts, interest rate swaps and cross currency swaps. Further details of derivative financial instruments are disclosed in notes 14 and 21.

Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to their fair value at each balance sheet date. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship. The Company designates certain derivatives as either hedges of the fair value of recognised assets or liabilities or firm commitments (fair value hedges), hedges of highly probable forecast transactions or hedges of foreign currency risk of firm commitments (cash flow hedges).

A derivative with a positive fair value is recognised as a financial asset whereas a derivative with a negative fair value is recognised as a financial liability. A derivative is presented as a current asset due after one year or a creditor due after more than one year if the remaining maturity of the instrument is more than 12 months and it is not expected to be realised or settled within 12 months. Other derivatives are presented as current assets or current liabilities.

Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the balance sheet date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Notes to the financial statements (continued)

for the year ended 31 August 2017

3. Critical accounting judgements and key sources of estimation uncertainty

In the application of the Company's accounting policies, which are described in note 2, the Directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The following are the critical judgements, apart from those involving estimations (which are dealt with separately below), that the directors have made in the process of applying the Company's accounting policies and that have the most significant effect on the amounts recognised in financial statements.

Fair value measurements and valuation processes

Some of the Company's assets and liabilities are measured at fair value for financial reporting purposes. In estimating the fair value of an asset or a liability, the Company uses market-observable data to the extent it is available.

Impairment of investments in subsidiaries

Determining whether the Company's investments in subsidiaries have been impaired requires estimations of the investments' values in use. The value in use calculations require the entity to estimate the future cash flows expected to arise from the investments and suitable discount rates in order to calculate present values. The carrying amount of investments in subsidiaries at the Balance sheet date was £10,810 million (2016: £11,051 million) with impairment loss of £85 million recognised in 2017 (2016: £1 million).

4. Auditor's remuneration

The fee in respect of auditing the 31 August 2017 accounts of the Company was £13,000 (2016: £13,000).

No non-audit services were provided to the Company by its auditor.

5. Staff numbers and costs

There were no employees during the current year (2016: nil):

No emoluments are payable to the Directors for their services to the Company in the current or preceding financial year.

6. Investment revenue

•	2017	2017	2016
		£million	£million
Interest receivable from bank deposits		7	1
Interest receivable from Group undertakings		286	241
Fair value gains on derivative financial instruments		20	72
Total interest receivable		313	314
Profit on disposal of investment		60	-
		373	314

7. Finance costs

		2017	2016
		£million	£million
Interest payable to Group undertakings	·	85	. 48
Financing fees		2	. З
Other finance costs	•	9	53
		96	104

8. Tax

An analysis of the tax charge for the year is presented as follows:

	2017 £million	2016 £million
Corporation tax:		
UK Corporation tax	(8)	· (1)
Adjustments in respect of prior periods	(6)	(1)
	. (14)	(2)

Corporation tax is calculated at 19.58% (2016: 20%) of the estimated taxable profit for the year.

Notes to the financial statements (continued)

for the year ended 31 August 2017

8. Tax (continued)

The lax charge for the year can be reconciled to the profit in the income statement as follows:

	2017 £million	2016 £million
Profit before tax	1,912	1,117
Tax at the UK corporation rate of 19.58% (2016: 20%)	(374)	(223)
Effects of:	•	
Group relief for nil payment	6	7
Income not taxable for tax purposes	23	35
Non-taxable dividends received	336	180
Adjustments in respect of prior periods	(5)	(1)
Tax charge for the year	(14)	(2)

Factors that may affect future current and total tax charges

In October 2015, the UK Government substantively enacted future reductions in the corporation tax rate by 1% from 1 April 2017 to 19% and a further 1% from 1 April 2020 to 18%. In September 2016, the UK Government enacted an additional 1% reduction from 1 April 2020 to 17%. The impact of this additional future reduction to 17% has been reflected in the current year.

9. Dividends

The Company's paid dividends are presented as follows:

	2017 £million	2016 £million
Amounts recognised as distributions to equity holders in the year		
First interim dividend for the year, equivalent to £0.29 per share	286	690
Second interim dividend for the year, equivalent to £0.34 per share	327	376
Third interim dividend for the year, equivalent to £0.56 per share	544	•
	1,157	1,066

10. Investments in subsidiaries

	Shares in subsidiary undertakings £million	Loans to Group undertakings £million
Cost		
At 1 September 2016	5,845	5,206
Additions	47	. (130)
Disposals	(48)	•
Reclassify to held for sale (note 13)	. (25)	.
At 31 August 2017	5,819	5,076
Provision for impairment		•
At 1 September 2016	•	•
Created	(85)	
At 31 August 2017	(85)	•
Carrying amount		
At 31 August 2016	5,845	5,206
At 31 August 2017	5,734	5,076

Subsidiary undertakings

The principal investments and disposals in subsidiary undertakings by the Company during the year were:

- On 24 March 2017 the Company disposed of its investment in Sleek International Limited in exchange for 1 ordinary share in The Boots Company PLC for consideration of £46 million. No gain or loss on disposal was generated.
- On 11 May 2017 the Company disposed of its £2 million investment in Walgreens Boots Alliance Asia Sourcing Limited to a fellow Group undertaking for consideration of \$80 million. This generated a gain on disposal of £60 million.

Notes to the financial statements (continued) for the year ended 31 August 2017

10. Investments in subsidiaries (continued)

The Company's subsidiary undertakings at the balance sheet date were:

	·	Percentage held by the Company or	
	•	subsidiary	· ·
	Share class	undertakings	Registered Office
Directly held			
WBA Acquisitions Luxco 7 S.a r.i.	Ordinary	100.0	59, Rue de Rollingergrund, Luxembourg, L-2440, Luxembourg
Alcura UK Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
Alliance Boots B.V.	Ordinary	100.0	210, Postbus, s-Hertogenbosch, 5201AE, Netherlands; 603, De Amert, Veghel, 5462 GH, Netherlands
Alliance Healthcare (Distribution) Limited	Ordinary	100.0	43, Cox Lane, Chessington, Surrey, KT9 1SN
Alliance Healthcare (IT Services) Limited	Ordinary	100.0	2, The Heights, Brooklands, Weybridge, Surrey, KT13 0NY
Alliance Healthcare Asia Pacific Limited	Ordinary	100.0	18/F Tesbury Centre, 28 Queen's Road East, Wanchai, Hong Kong
Alliance Healthcare España Holdings, S.L.	Ordinary	100.0	Av Virgen de Montserrat, 6, Pol Ind El Estruch, El Prat de Llobregat, Barcelona, 08820, Spain
Alliance Healthcare Limited	Ordinary	100.0	Block 3, Harcourt Centre, Harcourt Road, Dublin 2, Ireland
Alliance Healthcare Management Services Limited	Ordinary	100.0	43, Cox Lane, Chessington, Surrey, KT9 1SN
Alliance Healthcare Norge AS	Ordinary	100.0	P.o. boks 3554, Ski, 1402, Norway;
•	•		Snipetjernveien 10, Langhus, 1405, Norway
Alliance Healthcaré s.r.o.	Incorporated without shares	100.0	Praha 10, Podle trali 7, 108 00, Czech Republic
Alliance UniChem IP Limited	Ordinary	100.0°	2, The Heights, Brooklands, Weybridge, Surrey, KT13 0NY
Alloga UK Limited	Ordinary A, Ordinary B	100.0	Amber Park, Berristow Lane South Normanton, Alfreton, Derbyshire, DE55 2FH, England
Almus Pharmaceuticals Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL 2, The Heights, Brooklands, Weybridge, Surrey, KT13 0NY
3&B Capital Partners L.P.	Unincorporated entity	100.0	55, Blandford Street, London, W1U 7HW, England & Wales
Beachcourse Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2Ji
Beeston Site Services Limited	Ordinary	100.0	1 Thane Road West, Notlingham, NG2 3AA
	₹	100.0	1 Thane Road West, Notlingham, NG2 3AA, England
Boots Delivery Services Limited	Ordinary	100.0	
Boots International Limited	Ordinary		1 Thane Road West, Nottingham, NG2 3AA
Boots International Management Services Limited	Ordínarý	100.0	1 Thane Road West, Notlingham, NG2 3AA, England
Boots Korea Limited	Ordinary	100.0	1 Thane Road West, Nottingham, NG2 3AA, England
Boots Management Services Limited	Ordinary	100.0	1 Thane Road West, Notlingham, NG2 3AA, England 300, Maridalsveien, Oslo, 0872, Norway;
Boots Norge AS	Ordinary	100.0	P.o Box 4593 Nydalen, Oslo, Norway, 0404
Boots Optical Investment Holdings Limited	Ordinary	58.0	1 Thane Road West, Nottingham, NG2 3AA
Boots Opticians Limited	Ordinary .	100.0	1 Thane Road West, Nottingham, NG2 3AA
Boots Pensions Limited	Ordinary	100.0	1 Thane Road West, Nottingham, NG2 3AA Boots - North, 3rd Floor, 79 - 91 High Street, Falkirk, FK1
Boots Propco D Limited	Ordinary	100.0	1ES, Scotland Boots - North, 3rd Floor, 79 - 91 High Street, Falkirk, FK1
Boots Propco E Limited	Ordinary	100.0	1ES, Scotland Boots - North, 3rd Floor, 79 - 91 High Street, Falkirk, FK1
Boots Propco F Limited	Ordinary	100.0	1ES, Scotland Boots - North, 3rd Floor, 79 - 91 High Street, Falkirk, FK1
Boots Propco G Limited	Ordinary	100.0	1ES, Scotland Boots - North, 3rd Floor, 79 - 91 High Street, Falkirk, FK1
Boots Propco H Limited	Ordinary	100.0	1ES, Scotland
Soots Pure Drug Company Limited	Ordinary	100.0	D90, 1 Thane Road West, Notlingham, NG2 3AA 2F Block 71A, Park West Business Park, Nangor Road, Dublin
Boots Retail (Ireland) Limited	Ordinary	100.0	12, Ireland; 6th Floor, 2 Grand Canal Square, Dublin 2, Ireland
Nests Detail (Theiler d) Limits d	Ordinani	100.0	No 9, 8th Floor, Pakin Building, Ratchadapisek Road, Kwaeng
Roots Retail (Thailand) Limited	Ordinary	100.0	Dindang, Khet Dindang, Bangkok, Thailand
Boots The Chemists Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
Soots UK Limited	Ordinary	100.0	NOTTINGHAM, NG2 3AA
Caseview (P.L.) Limited	Ordinary	100.0	20, Alliance Court, Alliance Road, London, W3 0RB
200 Energy Limited	Ordinary	100.0	1 Thane Road West, Notlingham, NG2 3AA, England
Moss, Limited	Ordinary	100.0	1 Thane Road West, Notlingham, NG2 3AA
eamington Spa Properties (Two) Limited	Ordinary	100.0	1 Thane Road West, Nottingham, NG2 3AA, England The Green House Nicholson Road, Ryde, Isle of Wight, PO33
iz Earle Beauty Co, Limited	Ordinary, Ordinary A	100.0	1BG, England
OTC Direct Limited	Ordinary	100.0	43, Cox Lane, Chessington, Surrey, KT9 1SN
and G Investments Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
Sleek Capital Limited	Ordinary	100.0	1 Thane Road West, Nottingham, NG2 3AA
print Investments 5 Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C, 2JL

Notes to the financial statements (continued) for the year ended 31. August 2017

10. Investments in subsidiaries (continued)

		Percentage held by the	, · · · · ·
		Company or	•
	Observations	subsidiary	Desistent office
· · · · · · · · · · · · · · · · · · ·	Share class	undertakings	Registered Office
The Bools Company PLC	Ordinary	100.0	NOTTINGHAM, NG2 3AA
UniChem Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
Walgreens Boots Alliance Services Limited	Ordinary	100.0	2, The Heights, Brooklands, Weybridge, Surrey, KT13 0NY,
	•		England
Walgreens Boots Alliance Services MC S.A.M.	Ordinary	99.9	24, boulevard du Tenao, Entresols 3 et 2, 98000, Monaco
WBA Acquisitions UK Holdco 5 Limited	Ordinary	. 80.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
·	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
WBA Holdings 1 Limited	<u> </u>		
WBA Latin America Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
Indirectly held			
AA Asia Limited	Ordinary	100.0	8/F Tesbury Centre, 28 Queen's Road East, Wanchai, Hong
	•		Kong
AB Acquisitions Nederland Holdco 1 B.V.	Ordinary	100.0	603, De Amert, Veghel, 5462 GH, Netherlands
AB Property Holdings Limited	Ordinary	100.0	Avalon Trust & Corporate Services Limited, Landmark Square,
Ab Froperty Hololings Elimited	Oldinary	100.0	
•			1st Floor, 64 Earth Close, PO Box 715, Grand Cayman, KY1-
			1107, Cayman Islands
ABF, Administradora de Beneficios Farmacéuticos S.A	Ordinary	100.0	Miraflores 383, 6th Floor, Santiago, Chile
Administradora Fasa, S.A.	Ordinary .	100.0	Miraflores 383, 6th Floor, Santiago, Chile
Alcura Health España, S.A.	Ordinary	. 99.9	Calle Pisuerga, 21-25, Poligono Santa Margarita, Terrasa,
			Barcelona, Spain
Alliance BMP Limited	Ordinary	100.0	2, The Heights, Brooklands, Weybridge, Surrey, KT13 0NY
Alliance Healthcare Deutschland AG	Ordinary	94.9	Solmsstraße 73, Frankfurt am Main, 60486
	•	100.0	Solmsstraße 73, Frankfurt am Main, 60486
Alliance Healthcare Deutschland Holdings 1 GmbH	Ordinary		
Alliance Healthcare España S.A.	Ordinary	99.2	Av Virgen de Montserrat, 6, Pol Ind El Estruch, El Prat de
			Llobregat, Barcelona, 08820, Spain
Alliance Healthcare Italia (IT Services) Srl	Ordinary	100.0	Via Cesarea 11/10, Genova, 16121, Italy
Alliance Healthcare Management Services (Nederland) 8.V.	Ordinary	100.0	603, De Amert, Veghel, 5462 GH, Netherlands
D.V.	Ordinary	100.0	210, Postbus, s-Hertogenbosch, 5201AE, Netherlands;
Alliance Healthcare Nederland B.V.			603, De Amert, Veghel, 5462 GH, Netherlands
	Ordinary	100,0	Buyukdere Cad., Ali Kaya Sok., Polat Plaza B Blok No:4 K:13,
Alliance Healthcare Turkey Holding A.S.	•		Levent
randice regulatore rarkey residing rase.	Ordinary	100,0	Basin Ekspres Yolu, Kavak Sok. Eresinler Ser Plaza No:3, A
Alliana Haalibaan Validas Haldina Annaim Cidrali	Ordinary	100.0	Blok Kal:3, Yenibosna – Istanbul, 34530, Turkey
Alliance Healthcare Yatirim Holding Anonim Sirketi Alliance Santé - Distribuição Farmacêutica de Eulália	Ordinary	100.0	Rua 3, Lote E Matinha, Lisboa, 1900-823, Portugal
Pereira e Ramalho Fernandes, S.A.			•
Alliance UniChem Investments 4 Limited	Ordinary	· 100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
Alloga (Nederland) B.V.	Ordinary	100.0	603, De Amert, Veghel, 5462GH, Netherlands
	Ordinary	100.0	Avenida de la Industria, 29, P.I. la Cantuena, Fuenlabrada,
Alloga Logistica (España), S.L.			Madrid, E-28947, Spain
Alloga Logistics Romania	Ordinary	100,0	No 65A, Biroul 1, Traian Street, Rudeni, City Chitila, Ilfov
	•	100.0	
Alloga S.å r.l.	Ordinary		59, Rue de Rollingergrund, Luxembourg, L-2440, Luxembourg
	Ordinary	100.0	Av. Verge de Montserrat 6, Pol. Ind. Estruch, El Prat de
Almus Farmaceutica, S.A.			Llobregat, Barcelona, 08820, Spain, Barcelona
ANZAG Rostock GmbH & Co. KG	Ordinary	79.0	Toelzer Straße 15, 82031 Gruenwald
ANZAG Rostock Grundstucks-Verwaltungsgesellschaft	Ordinary	100.0	Toelzer Straße 15, 82031 Gruenwald
mbH			
Armila UAB	Ordinary	100.0	Ateities g.10, Vilnius
Aroma Actives Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
Aromatherapy Associates Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
Aromatherapy Associates, Inc	Ordinary	100.0	United States
	Ordinar		4000 Breater Bond Ots 400 Bitter T. MCCC 400
Aromatherapy Investments Holding Limited	Ordinary	97.6	4900 Presion Road, Ste 108, Frisco, Texas, 75034-8744,
	Deferred	100.0	United States
Aromatherapy Investments Limited	Ordinary	100.0	20-22 Bedford Row, London, WC1R 4JS
AS Logistik GmbH	Ordinary	100.0	Solmsstraße 73, Frankfurt am Main, 60486
B&B Capital Partners (GP) Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
B&B Capital Partners (SLP GP) Limited	Ordinary	100.0	Boots - North, 3rd Floor, 79 - 91 High Street, Falkirk, FK1
	• "		1ES, Scotland
B&B Investment Partners LLP	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
	O 11	100.0	Amtsgericht Offenbach, M 5HRB 2131, Germany
BCM Kosmetik GmbH	Ordinary		
3CM Kosmetik GmbH	Ordinary Ordinary A, Ordinary B	100.0	Avenida Fundadores 935, int.301, Colonia Valle de Mirador,
	· · · · · · · · · · · · · · · · · · ·		Avenida Fundadores 935, int.301, Colonia Valle de Mirador,
Benavides de Reynosa, S.A. de C.V.	Ordinary A, Ordinary B	100.0	Avenida Fundadores 935, Int.301, Colonia Valle de Mirador, Monterrey, Nuevo Leon, CP 64750, Mexico
Benavides de Reynosa, S.A. de C.V.	Ordinary A, Ordinary B Ordinary	100.0 77.5	Avenida Fundadores 935, Int.301, Colonia Valle de Mirador, Monterrey, Nuevo Leon, CP.64750, Mexico England & Wales
Benavides de Reynosa, S.A. de C.V. Blyth Pharmacy Limited	Ordinary A, Ordinary B	100.0	Avenida Fundadores 935, Int.301, Colonia Valle de Mirador, Monterrey, Nuevo Leon, CP.64750, Mexico England & Wales Boots - North, 3rd Floor, 79 - 91 High Street, Falkirk, FK1
Benavides de Reynosa, S.A. de C.V. Blyth Pharmacy Limited	Ordinary A, Ordinary B Ordinary Unincorporated entity	100.0 77.5 100.0	Avenida Fundadores 935, Int.301, Colonia Valle de Mirador, Monterrey, Nuevo Leon, CP.64750, Mexico England & Wales Boots - North, 3rd Floor, 79 - 91 High Street, Falkirk, FK1 1ES, Scotland
3CM Kosmetik GmbH Benavides de Reynosa, S.A. de C.V. Blyth Pharmacy Limited Boots 2 Property Partnership	Ordinary A, Ordinary B Ordinary	100.0 77.5	Avenida Fundadores 935, Int.301, Colonia Valle de Mirador, Monterrey, Nuevo Leon, CP.64750, Mexico England & Wales Boots - North, 3rd Floor, 79 - 91 High Street, Falkirk, FK1

Notes to the financial statements (continued) for the year ended 31 August 2017 10. Investments in subsidiaries (continued)

·		Percentage held by the Company or subsidiary	•
•	Share class	undertakings	Registered Office
Boots Benevolent Fund	Ordinary	100.0	1 Thane Road West, Nottingham, NG2 3AA
Boots Charitable Trust	Ordinary	100.0	1 Thane Road West, Nottingham, NG2 3AA
Boots Contact Lenses Limited	Ordinary	100.0	1 Thane Road West, Nottingham, NG2 3AA, England
Boots Eyewear Limited	Ordinary	100.0	1 Thane Road West, Nottingham, NG2 3AA, England
Boots Nederland B.V.	Ordinary	100.0	210, Postbus, s-Hertogenbosch, 5201AE, Netherlands; 603, De Amert, Veghel, 5462 GH, Netherlands
Boots Opticians Professional Services Limited	Ordinary	100.0	1 Thane Road West, Nottingham, NG2 3AA, England
Boots PropCo A Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2
Boots PropCo B Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2
Boots PropCo Beeston Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2
Boots PropCo C Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2
Boots PropCo Flex Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2
Boots PropCo Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2
Boots PropCo Retail Flex Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2
Boots Properties Limited	Ordinary	100.0	NOTTINGHAM, NG2 3AA
Bools Property HoldCo Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2
Boots Property Partnership	Unincorporated entity	100.0	Boots - North, 3rd Floor, 79 - 91 High Street, Falkirk, FK1 1ES, Scotland
Boots Property Scottish Limited Partnership	Unincorporated entity	100.0	Boots - North, 3rd Floor, 79 - 91 High Street, Falkirk, FK1 1ES. Scotland
Brandhandling International Limited	Ordinary	100.0	ILS Fiduciary (B.V.I.) Limited, P.O. Box 3085, Road Town, Tortola, British Virgin Islands
Casa Saba Brasil Holdings, Ltda	Quotas	100.0	Av. Das Americas, 2000, Loja 5 Parte, Barra de Tijuca, Rio Janeiro, CEP 22640-101, Brazil
Centro Farmaceutico Asturiano, S.A.	Ordinary	97.7	C/ Calderon de la Barca 16, Oviedo, Asturias, Spain
Class Delta Limited	Ordinary A, Ordinary B	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2
Comercializadora y Distribuldora BF S.A.	Ordinary	100.0	Miraflores 383, 6th Floor, Santiago, Chile Avenida Fundadores 935, Int. 301, Colonia Valle de Mirador
Comercializadora y Servicios Benavides, S.A. de C.V.	Ordinary	100.0	Monterrey, Nuevo Leon, CP.64750, Mexico
Compañia de Nutrición General S.A.	Ordinary	100.0	Miraflores 383, 6th Floor, Santiago, Chile
CPL Pharma Lager und Vertrieb GmbH	Ordinary	100.0	Solmsstraße 73, Frankfurt am Main, 60486
DDM Healthcare Limited	Ordinary	100.0	Boots - North, 3rd Floor, 79 - 91 High Street, Falkirk, FK1 1ES, Scotland
Distrilife, Distribuidora Atacadista de Suplementos Alimenticios, Ltda	Quotas	100.0	147, Galpao 4, sala 17, Av. Talma Rodrigues Ribeiro, 147, Galpao 4, sala 17, Portal do Jacaraipe, Serra/ES, CEP 291 795, Espiritu Santo, Brazil, 29173-795, Brazil
Dollond & Aitchison Limited	· Ordinary	100.0	1 Thane Road West, Nottingham, NG2 3AA, England
Droguerla, Distribuidora y Logistica DLI S.A.	Ordinary	100.0	Miraflores 383, 6th Floor, Santiago, Chile
sko Itriyat Sanayi ve Ticaret Anonim Sirketi	Ordinary	100.0	50. Yil Mahallesi 2107 Sokak, No: 27 Sultan Ciftligi – Gosmansapa, Istanbul, Turkey
armacias ABC de Mexico, S.A. de C.V.	Ordinary	100.0	Avenida Chapultepec Sur, 249, Colonia Americana, Zapopa
armacias Ahumada S.A.	Ordinary	100.0	Jalisco, C.P. 44160, Mexico Miraflores 383, 6th Floor, Santiago, Chile
armacias Benavides S.A.B. de C.V.	Ordinary	96.6	Avenida Fundadores 935, int.301, Colonia Valle de Mirador
ARMEXPERT D.C.I. SRL	Ordinary	100.0	Monterrey, Nuevo Leon, CP.64750, Mexico Amilcar C. Sandulescu no. 7, 6th district, Bucharest, Romar
asa Investment Limitada	Un-incorporated entity	100.0	Av. Las Condes, No 14,791, 01, comuna de Lo Barnechea, Santiago, Chile
orte Direct Limited	Ordinary	100.0	43, Cox Lane, Chessington, Surrey, KT9 1SN
orte Pharma Group Limited	Ordinary	100.0	43, Cox Lane, Chessington, Surrey, KT9 1SN
orte Pharma Limited	Ordinary	100.0	43, Cox Lane, Chessington, Surrey, KT9 1SN
SESDAT Gesellschaft für Informationsmanagement mbH	Ordinary	100.0	Solmsstraße 41, 60486 Frankfurt am Main c/o Hardie Caldwell LLP, Citypoint 2, 25 Tyndrum Street,
Sovanhill Pharmacy Limited	Ordinary	52.9	Glasgow, G4 0JY
ledef International Holdings BV	Ordinary	100.0	603, De Amert, Veghel, 5462 GH, Nelherlands
nversiones Internacionales Inverfar S.A.	Ordinary	100.0	Av. Las Condes, No 14,791, 01, comuna de Lo Barnechea, Santiago, Chile
ring apotheek B.V. aboratorios MDK S.A.	Ordinary Ordinary	51.0 100.0	603, De Amert, Veghel, 5462 GH, Netherlands Miraflores 383, 6th Floor, Santlago, Chile
lareks Ecza Deposu Ticarel Anonim Şirketi	Ordinary	100.0	Istanbul Esenler Oruc Reis Mh. Giyimkent St. 2.Sk.D3 B19 N.34-35 Istanbul
lexiapharma, S.L.	Ordinary	100.0	Poligono Industrial Las Atalayas, finca numero 1, Alicante, Alicante, 03114, Spain
hD Acquisition Bidco Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2
hD Acquisition Midco Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2.
hD Nutrition Limited	Ordinary .	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2.
amuneles Vaistine UAB ervicios Generales Benavides, S.A.de C.V.	Ordinary Ordinary	100.0 100.0	Taikos st. 4-1, Elektrenai, Lithuania Avenida Fundadores 935, Int.301, Colonia Valle de Mirador Manteres Nuevo Leon CR 64750, Maries
	•		Monterrey, Nuevo Leon, CP.64750, Mexico

Notes to the financial statements (continued)

for the year ended 31 August 2017

10. Investments in subsidiaries (continued)

	Share class	Percentage held by the Company or subsidiary undertakings	Registered Office
Servicios Operacionales Benavides, S.A. de C.V.	Ordinary	100.0	Avenida Fundadores 935, int.301, Colonia Valle de Mirador,
			Monterrey, Nuevo Leon, CP.64750, Mexico
Skills in Healthcare GmbH Deutschland	Ordinary	100.0	Solmsstraße 73, Frankfurt am Main, 60486
Skills in Healthcare Romania S.r.I.	Ordinary	100.0	Amilcar C. Sandulescu no. 7, 6th district, Bucharest, Romania
Snipetjernvelen 10 AS	Ordinary	100.0	Snipetjernveien 10, Langhus, 1405, Norway
Soap & Glory GmbH	Ordinary	100.0	c/o Andreas Korth, KPMG Rechsanwaltsgesellschaft mbH, Ganghoterstrasse 29, Munich, 80339, Germany; LS-LP Loth, Tuerkenstr. 9, Munich, 80333, Germany
Soap & Glory Limited	Ordinary	100.0	1 Thane Road West, Nottingham, NG2 3AA, England
Spa Strategy Limited	Ordinary A	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JI
Spits B.V.	Ordinary	100.0	603, De Amert, Veghel, 5462 GH, Netherlands
SportsPlatform Holdco Limited	Ordinary A	81.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
SportsPlatform Midco Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
Sprint Investments 1 Limited	Ordinary	80.0	The Heights Brooklands, Weybridge, Surrey, KT13 0NY, England
Stephar B.V.	Ordinary	100.0	5, Van der Glessenweg, Krimpen ad IJssel, 2921LP, Netherlands; 710, Postbus, Krimpen ad IJssel, 2920CA, Netherlands
The Refinery Limited	Ordinary A, Ordinary B	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
TPW Acquisition Bidco Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
TPW Acquisition Midco Limited	Ordinary	100.0	Sedley Place, 4th Floor, 381 Oxford Street, London, W1C 2JL
vitasco GmbH	Ordinary	100.0	Solmsstraße 73, Frankfurt am Main, 60486
W.H.C.P. (Dundee) Limited	Ordinary	57.5	Wallacetown Health Centre, Lyon Street, Dundee, DD4 6RB
WBA Group Limited	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL
WBA Holdings 2	Ordinary	100.0	Sedley Place, 4th Floor, 361 Oxford Street, London, W1C 2JL

11. Interests in associates

		£million
Cost		
At 1 September 2016		29
Disposals		(18)
At 31 August 2017		11
Carrying amount		
At 31 August 2016		29
At 31 August 2017		11

The principal movements in interests in associates by the Company during the year were:

On 18 October 2016 Alliance Healthcare S.A., of whom the Company is a 49% shareholder, made a reduction of paid in capital totalling €40 million. This resulted in a reduction of €20 million (£17 million) in the investment held by the Company. The reduction of €20 million (£17 million) was distributed to the Company.

The Company's associate undertakings at the balance sheet date are presented as follows:

	Share class	Percentage held by the Company or subsidiary undertakings	
Alliance Healthcare S.A.	Ordinary	49.0	Rua 3, Lote E - Matinha, Lisbon, 1900-823, Portugal
Walgreens Boots Alliance Luxembourg S.a.r.l. B&B Capital Partners (SLP) L.P.	Ordinary Ordinary	35.0 43.3	59, Rue de Rollingergrund, Luxembourg, L-2440, Luxembourg Boots - North, 3rd Floor, 79 - 91 High Street, Falkirk, FK1 1ES, Scotland
Nottingham Enterprise Zone Development Company Limited	Ordinary	50.0	1 Thane Road West, Nottingham, NG2 3AA
Prodak Kosmetik Sp. z o.o.	Ordinary	20.0	Ludowa 61 B, 58304 Walbrzych, Poland

Notes to the financial statements (continued)

for the year ended 31 August 2017

12. Other investments

	2017 £million	2016 £million
Available-for-sale investments:		
Listed equity	32	16
Unlisted equity	•	<u>-</u>
Total investments	32	16

The principal movements in other investments by the Company during the year were:

On 18 January 2017 the Company completed the acquisition of further shares in Russian Pharmacy Chain 36.6 to bring its shareholding back to
 15 per cent following the merger between Russian Pharmacy Chain 36.6 and A5 Pharmacy Retail Limited.

The Company's investment in listed equity represents a strategic non-controlling interest of 15 per cent in Russian Pharmacy Chain 36.6 amounting to £32 million. These shares are not held for trading and accordingly are classified as available-for-sale. Although the shares are listed, due to the limited liquidity of shares traded the share price is not considered a reliable indicator of fair value and as such the investment is accounted for at cost less impairment.

13. Assets held for sale

		£million
At 1 September 2016		-
Reclassified from investments in subsidiaries (note 10)		25
Additional cash investment		48
Additional cash investment Fair value losses on held for sale assets	·	(33)
		40

The Company's investments classified as held for sale at the balance sheet date are presented as follows:

	Share class	Percentage held by the Company	Registered Office
BCM Employment & Management Services Limited	Ordinary	100.0	2, The Heights, Brooklands, Weybridge, Surrey, KT13 0NY
BCM Limited	Ordinary	100.0	1 Thane Road West, Nottingham, NG2 3AA
BCM Specials Limited	Ordinary	100.0	1 Thane Road West, Nottingham, NG2 3AA

On 25 July 2017, the Group announced its intent to enter into a 10-year global agreement for the manufacture and supply of own beauty brands and private label products with Fareva S.A. Under the terms of the offer, Fareva S.A. will take ownership of the Group's contract manufacturing business, which includes BCM Limited, BCM Specials Limited and BCM Employment & Management Services Limited. The sale was completed on 31 October 2017

On 25 August 2017 the Company subscribed to one share in BCM Limited for consideration of £48 million.

14. Trade and other receivables

	2017 £million	2016 £million
Amounts falling due within one year:		
Amounts owed by Group undertakings	2,307	1,593
Other receivables	•	16
Included in current assets	2,307	1,609
Total trade and other receivables	2,307	1,609

15. Derivative financial instruments

	2017 £million	2016 £million
Financial assets carried at fair value through profit or loss	•	
Derivatives that are not designated in hedge accounting relationships:	8	33
Financial liabilities carried at fair value through profit or loss		
Derivatives that are not designated in hedge accounting relationships:	(20)	(6)

Further details of derivative financial instruments are provided in note 21.

Notes to the financial statements (continued)

for the year ended 31 August 2017

16. Borrowings

	2017	2016
<u> </u>	£million	£million
Amounts owed to Group undertakings	3,423	4,676
	3,423	4,676
	2017	2016
	£million	£million
Amounts due for settlement within one year:		
Amounts owed to Group undertakings	2,201	530
	2,201	530
Amount due for settlement after 12 months:		
Amounts owed to Group undertakings	1,222	4,146
	1,222	4,146

Borrowings owed to Group undertakings are variable and fixed rate committed loans that mature between 2017 and 2019. These loans, which are denominated in Sterling, Euro and U.S dollars are fully drawn and their carrying value at 31 August 2017 was £3,423 million (2016: £4,676 million).

17. Trade and other payables

	2017 £million	2016 £million
Amounts falling due within one year:		
Amounts owed to Group undertakings	3,290	2,157
Other creditors		12
Corporation tax	21	11
	3,316	2,180

. 18. Share capital

	2017 £million	2016 £million
Authorised Unlimited ordinary shares of 37% pence each (2016: unlimited shares)		Unlimited
Issued and fully paid		
973,905,943 ordinary shares of 371/39 pence each (2016: 973,903,943 ordinary shares of 371/39 pence each)	362	362

The Company has one class of ordinary shares which carry no right to fixed income.

19. Share premium account

	£million
At 1 September 2016	2,071
Share premium reduction	(2,071)
At 31 August 2017	

In January 2017, the share premium of the Company was reduced by £2,071 million.

20. Retained earnings

	Capital redemption reserve £million	Profit and loss account £million
At 1 September 2015	29	4,389
Profit for the period	•	1,115
Dividends paid	<u> </u>	(1,066)
At 31 August 2016	29	4,438
Share premium reduction	•	2,071
Profit for the year	•	1,898
Dividends paid	•	(1,157)
Other comprehensive income	·	(33)
At 31 August 2017	29	7,217

Notes to the financial statements (continued)

for the year ended 31 August 2017

21. Financial instruments

Categories of financial instruments held at fair value:

	2017 £million	2016 £million
Financial assets carried at fair value through profit or loss		-
Derivatives that are not designated in hedge accounting relationships:	8 .	33
Financial liabilities carried at fair value through profit or loss		
Derivatives that are not designated in hedge accounting relationships:	(20)	(6)

Profit for the year is after crediting:

	2017 £million	2016 £million
Financial assets at fair value		
At fair value through profit or loss	 20	72
Financial liabilities at fair value	· · · · · · · · · · · · · · · · · · ·	
At fair value through profit or loss		-

The fair values of financial assets and financial liabilities are determined as follows.

• The fair values of derivative instruments namely foreign exchange forward contracts are calculated using quoted prices. Where such prices are not available, a discounted cash flow analysis is performed using the applicable yield curve for the duration of the instruments for non-optional derivatives, and option pricing models for optional derivatives. Foreign currency forward contracts are measured using quoted forward exchange rates and yield curves derived from quoted interest rates matching maturities of the contracts. Interest rate swaps are measured at the present value of future cash flows estimated and discounted based on the applicable yield curves derived from quoted interest rates.

22. Contingent liabilities

With effect from 25 April 2012, the Company became Guarantor for two office leases. These leases expire on 23 June 2019 and have a maximum liability of £2 million.

23. Ultimate parent undertaking

At 31 August 2017, the Company's immediate parent company was WBA Acquisitions UK Holdco 7 Limited and its ultimate parent company and controlling party was Walgreens Boots Alliance, Inc. Walgreens Boots Alliance, Inc. is also the parent undertaking of the largest and only group in which the Company is consolidated. The consolidated financial statements of this group are available from the Walgreens Boots Alliance website at www.walgreensbootsalliance.com.

Walgreens Boots Alliance, Inc. is incorporated in the United States of America, and its principal office address is 108 Wilmot Road, Deerfield, Illinois, 60015.